<DOC>
	<DOCNO>NCT01610830</DOCNO>
	<brief_summary>Henoch Schonlein Purpura ( HSP ) , vasculitis small vessel deposit IgA , consider many author systemic form Berger 's disease ( IgA-N ) . IgA-N characterized IgA1 deposit mesangial area associate mesangial proliferation . These two disease remain leading cause ESRD primitive glomerulopathy Western country . In recent year , considerable progress make understanding pathophysiological mechanism IgA-N . However , high rate proteinuria one year presence severe glomerular inflammation renal biopsy remain predictor long term renal function . Moreover , high variability HSP clinical expression , purpura skin lesion evolve favourably spontaneously , rapidly progressive renal failure , remain far unexplained suggests existence individual genetic susceptibility . In first part study , study key factor base physiopathological data obtain laboratory well group . The second part study concern genetic factor . Although candidate gene may confer particular susceptibility disease , progress ESRD respond treatment many , gene involve inflammation control renin-angiotensin system particular interest . We apply result study patient HSP show three distinct phenotype ( HSP isolate cutaneous purpura associate minimal severe renal disease ) diagnosis clinical remission . The purpose study ass whether phenotype diagnosis associate physiological marker one predict pejorative evolution renal disease 1 year . Meanwhile , study polymorphism select gene interest could allow identification patient specific genetic susceptibility bad prognosis factor would thus eligible specific treatment .</brief_summary>
	<brief_title>Identification Biomarkers Predictive Worse Prognosis Henoch Schonlein Purpura</brief_title>
	<detailed_description />
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Schoenlein-Henoch</mesh_term>
	<criteria>Patients HSP whose diagnosis confirm histology active skin lesion , sign informed consent form minor , signature holder parental authority . Patients skin lesion ; Patients receive immunosuppressive drug steroid 2 week ; Patients another diagnosis ( platelet &lt; 100,000/mm3 , bacterial purpura , systemic disease ) ; Patients unable understand protocol , refuse sign information form unable comply regular followup consultation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Purpura , Schoenlein-Henoch</keyword>
	<keyword>adult</keyword>
	<keyword>child</keyword>
	<keyword>pronostic factor</keyword>
</DOC>